Impact of HLA alloimmunization in gene-modified autologous stem cell transplant for transfusion-dependent thalassemia

N Nora M. Gibson (1Cell Therapy and Transplant Section, Division of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA) E Eugene Khandros (1Division of Hematology, Children’s Hospital of Philadelphia, Philadelphia, PA) C Caitlin W. Elgarten (1Cell Therapy and Transplant Section, Division of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA) E Elizabeth Worster (3Children's Hospital of Philadelphia, Cell Therapy and Transplant Section, Division of Oncology, Department of Pediatrics, Philadelphia, United States) D Dimitrios S. Monos (3Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Philadelphia, PA) A Alexis A. Thompson (Children’s Hospital of Philadelphia, Philadelphia) J Janet L. Kwiatkowski (1Division of Hematology, Children’s Hospital of Philadelphia, Philadelphia, PA) T Timothy S. Olson (1Division of Hematology, Children’s Hospital of Philadelphia, Philadelphia, PA)

Abstract

Abstract We report our single-center experience demonstrating that HLA class I alloimmunization predicts longer time to platelet engraftment, increased bleeding complications, and higher transfusion requirements in patients undergoing gene-modified hematopoietic stem cell transplant for transfusion-dependent β thalassemia.

Article Details

Journal Blood
Volume / Issue Vol. 145, Issue 22
Published May 29, 2025
Pages 2666-2670
ISSN 0006-4971
Publisher Elsevier BV

Journal Info

Blood

Elsevier BV

ISSN: 0006-4971 Health Sciences

Authors (8)

N

Nora M. Gibson

1Cell Therapy and Transplant Section, Division of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA

E

Eugene Khandros

1Division of Hematology, Children’s Hospital of Philadelphia, Philadelphia, PA

C

Caitlin W. Elgarten

1Cell Therapy and Transplant Section, Division of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA

E

Elizabeth Worster

3Children's Hospital of Philadelphia, Cell Therapy and Transplant Section, Division of Oncology, Department of Pediatrics, Philadelphia, United States

D

Dimitrios S. Monos

3Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Philadelphia, PA

A

Alexis A. Thompson

Children’s Hospital of Philadelphia, Philadelphia

J

Janet L. Kwiatkowski

1Division of Hematology, Children’s Hospital of Philadelphia, Philadelphia, PA

T

Timothy S. Olson

1Division of Hematology, Children’s Hospital of Philadelphia, Philadelphia, PA